Humacyte, Inc. (HUMAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 800K 1.6M 2.4M Q4 '24: 0 Q1 '25: 517K Q2 '25: 818K Q3 '25: 1.6M Q4 '25: 2M Q1 '26: 2M Q2 '26: 2.1M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

-12M -8M -4M 0 4M 8M 12M Q4 '24: 0 Q1 '25: 370K Q2 '25: 458K Q3 '25: 951K Q4 '25: -7.7M Q1 '26: -9.6M Q2 '26: -10.5M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -42.6M Q4 '21: -81.2M Q1 '22: -83.2M Q2 '22: -82.5M Q3 '22: -85.4M Q4 '22: -84.6M Q1 '23: -85.3M Q2 '23: -93.5M Q3 '23: -94.7M Q4 '23: -100M Q1 '24: -104.1M Q2 '24: -106.9M Q3 '24: -112.5M Q4 '24: -114.4M Q1 '25: -111M Q2 '25: -111.2M Q3 '25: -105.4M Q4 '25: -108.1M Q1 '26: -113.9M Q2 '26: -111.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -49.9M Q4 '21: -26.5M Q1 '22: -26M Q2 '22: 28.1M Q3 '22: 34.3M Q4 '22: -12M Q1 '23: -29.1M Q2 '23: -88.7M Q3 '23: -89.4M Q4 '23: -110.8M Q1 '24: -105.7M Q2 '24: -139.7M Q3 '24: -152.9M Q4 '24: -148.7M Q1 '25: -77.7M Q2 '25: -58.7M Q3 '25: -37M Q4 '25: -40.8M Q1 '26: -97.6M Q2 '26: -96.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 5M 10M 15M Q4 '24: 0 Q1 '25: 147K Q2 '25: 360K Q3 '25: 620K Q4 '25: 9.7M Q1 '26: 11.6M Q2 '26: 12.6M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -60M Q4 '21: -81.2M Q1 '22: -85.4M Q2 '22: -87.3M Q3 '22: -73.6M Q4 '22: -71.1M Q1 '23: -71M Q2 '23: -77M Q3 '23: -73.2M Q4 '23: -73.3M Q1 '24: -82M Q2 '24: -80.7M Q3 '24: -90.6M Q4 '24: -98.1M Q1 '25: -99.4M Q2 '25: -104.5M Q3 '25: -105.5M Q4 '25: -105M Q1 '26: -101.5M Q2 '26: -97.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-120M -80M -40M 0 40M 80M 120M Q3 '21: -60.2M Q4 '21: -81.4M Q1 '22: -85.7M Q2 '22: -87.6M Q3 '22: -74M Q4 '22: -72.2M Q1 '23: -73.2M Q2 '23: -79.5M Q3 '23: -76M Q4 '23: -75.6M Q1 '24: -83.5M Q2 '24: -81.9M Q3 '24: -92.3M Q4 '24: -99.7M Q1 '25: -100.8M Q2 '25: -106.3M Q3 '25: -106.4M Q4 '25: -105.9M Q1 '26: -102.4M Q2 '26: -97.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 5.8M Q1 '21: 5.9M Q2 '21: 5.9M Q3 '21: 44M Q1 '22: 103M Q2 '22: 103.9M Q3 '22: 103M Q1 '23: 103.3M Q2 '23: 103.4M Q3 '23: 103.4M Q1 '24: 108.2M Q2 '24: 119.2M Q3 '24: 119.4M Q1 '25: 131.8M Q2 '25: 155.4M Q3 '25: 158.3M Q1 '26: 197.8M Q2 '26: 234.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '21: -9.87 Q4 '21: -0.66 Q1 '22: 2.61 Q2 '22: 5.85 Q3 '22: 6.32 Q4 '22: -0.12 Q1 '23: -0.29 Q2 '23: -0.86 Q3 '23: -0.86 Q4 '23: -1.07 Q1 '24: -1.00 Q2 '24: -1.26 Q3 '24: -1.34 Q4 '24: -1.26 Q1 '25: -0.69 Q2 '25: -0.45 Q3 '25: -0.23 Q4 '25: -0.26 Q1 '26: -0.63 Q2 '26: -0.55 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.